USANA Health Sciences (NYSE:USNA) Rating Increased to Strong-Buy at StockNews.com

StockNews.com upgraded shares of USANA Health Sciences (NYSE:USNA) from a buy rating to a strong-buy rating in a report issued on Saturday.

Separately, DA Davidson raised USANA Health Sciences to a “hold” rating in a research report on Friday, December 20th.

USANA Health Sciences Stock Performance

USNA stock opened at $35.29 on Friday. The business’s 50 day moving average price is $37.88 and its two-hundred day moving average price is $39.84. The company has a market capitalization of $672.63 million, a price-to-earnings ratio of 12.47, a price-to-earnings-growth ratio of 1.25 and a beta of 0.89. USANA Health Sciences has a fifty-two week low of $31.44 and a fifty-two week high of $54.81.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.07. The business had revenue of $200.22 million during the quarter, compared to the consensus estimate of $208.45 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. During the same quarter last year, the firm earned $0.59 earnings per share. Sell-side analysts forecast that USANA Health Sciences will post 2.45 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Gilbert A. Fuller sold 675 shares of the company’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $37.71, for a total value of $25,454.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.33% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On USANA Health Sciences

A number of institutional investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. lifted its position in USANA Health Sciences by 9.2% during the third quarter. Franklin Resources Inc. now owns 21,050 shares of the company’s stock valued at $750,000 after purchasing an additional 1,771 shares during the last quarter. Barclays PLC boosted its holdings in shares of USANA Health Sciences by 111.9% in the third quarter. Barclays PLC now owns 27,737 shares of the company’s stock valued at $1,052,000 after purchasing an additional 14,647 shares during the period. Geode Capital Management LLC grew its position in shares of USANA Health Sciences by 4.5% during the 3rd quarter. Geode Capital Management LLC now owns 297,120 shares of the company’s stock worth $11,269,000 after buying an additional 12,898 shares in the last quarter. State Street Corp lifted its position in shares of USANA Health Sciences by 0.6% in the 3rd quarter. State Street Corp now owns 435,164 shares of the company’s stock worth $16,501,000 after purchasing an additional 2,782 shares during the period. Finally, Safe Harbor Fiduciary LLC bought a new stake in USANA Health Sciences during the third quarter valued at about $30,000. 54.25% of the stock is owned by hedge funds and other institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.